CY 1503

Drug Profile

CY 1503

Alternative Names: CY-1503; Cylexin

Latest Information Update: 26 Apr 1999

Price : $50

At a glance

  • Originator Epimmune
  • Class Anti-inflammatories; Anti-ischaemics
  • Mechanism of Action Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Reperfusion injury; Respiratory tract disorders

Most Recent Events

  • 26 Apr 1999 Discontinued-III for Reperfusion injury in USA (Unknown route)
  • 26 Apr 1999 Discontinued-III for Reperfusion injury in Canada (Unknown route)
  • 26 Apr 1999 Discontinued-II for Respiratory tract disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top